The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity

The oncolytic adenovirus Delta24-RGD represents a new promising therapeutic agent for patients with a malignant glioma and is currently under investigation in clinical phase I/II trials. Earlier preclinical studies showed that Delta24-RGD is able to effectively lyse tumor cells, yielding promising r...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kleijn, Anne, Kloezeman, Jenneke, Treffers-Westerlaken, Elike, Fulci, Giulia, Leenstra, Sieger, Dirven, Clemens, Debets, Reno, Lamfers, Martine
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2014
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4035348/
https://ncbi.nlm.nih.gov/pubmed/24866126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0097495
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky